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1. Introduction
Superior sulcus tumours are rarely encountered in clinical practice, representing < 5% of all
bronchogenic carcinomas [1, 2]. In 1932, Pancoast [3] published his classic article in which he
reported four patients who had a similar presentation including pain in the shoulder and arm,
weakness and wasting of the muscles of the hand, and ipsilateral Horner syndrome together
with a lesion situated at the apex of the lung. Pancoast [3] rejected the pulmonary origin of the
tumour that was recognised by Tobias [4], who described the same clinical syndrome in four
other patients.
Pancoast syndrome is due to lesions extending to the superior thoracic inlet. Specific symp‐
tomatology mainly due to brachial plexus invasion accounts for the majority of those cases
[5-7]. Pancoast tumour is a tumour of the apex of the lung with no intervening lung tissue
between tumour and chest wall. Subsequently, there is an involvement of structures of the
apical chest wall above the level of the second rib. Almost half of the treated cancers are
squamous cell carcinomas (45-50%), while the rest are either adenocarcinomas (36-38%) or
undifferentiated large-cell carcinomas (11-13%). The tumour rapidly involves the structures
of the thoracic inlet & the root of neck. Due to its localisation in the apex of the lung, invasion
of the lower part of the brachial plexus, first ribs, vertebrae, subclavian vessels or stellate
ganglion, occurs [8-10]. The classical Pancoast presentation, with shoulder pain radiating to
the ulnar side of the arm and the hand, is presented in 55 to 60% of the patients. Pain at the
ulnar aspect of the forearm and hand is consistent with T1 involvement; furthermore symp‐
tomatology along the intrinsic hand muscles suggests the C8 root or lower trunk tumour
deposits. Horner's syndrome is reported in up to 30% of the cases.
Superior sulcus tumours are not necessarily associated with the classic Pancoast syndrome.
Though some controversy exists about their exact definition, it is generally accepted that they
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may be defined as primary lung cancers involving the apex of the chest wall and usually
associated with pain in the shoulder and/or arm[9, 10].
Although those tumours represent a wide range of stage IIB to stage IV disease, (IIB (25-27%), stage
IIIA (6-8%), stage IIIB (40-42%) and stage IV (21-23%) it is the T3, T4, N0-N1 subgroup of this
spectrum that could be amenable to surgical intervention [11]. This subgroup of patients (less than
5% of Bronchogenic Carcinomas) however, is difficult to be treated surgically due to the loca‐
tion of the tumour and the complex anatomy of the area involved [12]. Historically, Pancoast
tumours have been associated with high rates of incomplete resection, local recurrence, and death.
Pancoast tumours were thought to be located posteriorly and early attempts to resect those
tumours were approached solely from the back. A percentage of these lesions might also be located
at the front, with vascular rather than neuro-vertebral involvement. Various reports suggested
spinal involvement in 15%, brachial plexus in 15% and subclavian vessels in 6% of the cases [13].
Therefore surgeons treating these cancers should be able to be familiar and adapt with the various
approaches. An understanding of the posterior location of neural structures and somewhat
anterior location of vascular structures is important for adequate operative planning.
This article alludes to the anatomy, initial assessment, and surgical approaches with an
emphasis on the modified anterior approach for these cancers.
2. How does the treatment of pancoast tumours evolved the last decades
For more than 40 years the treatment of Pancoast tumours has centred on a bi-modality
regimen consisting of preoperative external beam radiotherapy followed by surgery. Tri-
modality treatment however with the addition of platinum based chemotherapy regimes has
become currently the standard treatment, in order to achieve additive anti-tumour effects
(chemotherapy as radiation sensitiser). According to Wright et al [14] induction chemo-
radiotherapy (CT/RT) can be administered with low morbidity, a higher complete resection
rate, a high pathologic response rate, a reduced loco-regional recurrence rate and improved
survival. Further improvement in radiotherapy with the advent of 3-dimensional conformal
radiotherapy, the total radiation dose that could be safely delivered was not anymore con‐
strained by dose-limiting toxicities upon the nearby organs.
Careful patient selection for tri-modality treatment, on the basis of staging and comorbidity, is of
vital importance in the treatment of Pancoast tumours. Nevertheless only 30% of M0 patients with
Pancoast tumours were eligible for combined treatment according to Pourel et al [15]. Not only
operability (patient fitness to surgery) but also ability to resect the tumour is of a major impor‐
tance bearing in mind the difficulty of access, the crowded anatomy of this region and the tendency
of the tumours in this area to involve important adjacent structures. As per the same group [15],
following CT/RT, 67% of the patients were amenable to thoracotomy. The resection rate, which
had remained unchanged at approximately 50%for almost 40 years with conventional preopera‐
tive radiotherapy, was improved to above 70% in SWOG [16] and JCOG [17] studies.
Preoperative radiotherapy was part of the standard treatment, but a recent prospective phase
II study (Southwest Oncology Group 9416, INT 0160)[16], suggests that preoperative concur‐
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rent CT/RT (platinum-based chemotherapy and 45Gy of radiotherapy) improves the rate of
complete resection, local recurrence, and intermediate-term survival. Like wise, the Japan
Clinical Oncology Group JCOG trial 9806 [17]in a prospective report concluded along the same
lines. Furthermore, Kwong et al [18] reported that high dose radiotherapy targeting up to 60
Gy (rather than 45 Gy) could be given in the neoadjuvant setting; it is successfully tolerated
and associated with improved resection rate.
3. Applied surgical anatomy
The limited access and poor visualisation of the thoracic inlet is due to: 1) the unique course
of the upper ribs downwards and outwards that render the neuro-vascular bundle inaccessible
to posterior approaches, 2) the musculature of the area and also 3) the overlapping bulky
pectoral-shoulder girdle with the clavicle and the manubrium to further restrict access from
the neck. These anatomical idiosyncrasies create a hostile but challenging environment for the
thoracic surgeon.
The main goal for cure is to achieve local control of the disease and aim for relapse-free,
metastasis-free outcome. Local control is obtained by removing the upper lobe, chest wall and
invaded structures (subclavian artery or vertebra), aiming for R0 resection margins. Radically
resected cases yield better survival whereas R1 resections are associated with high incidence
of local and distal recurrences. Involvement of the vertebral body or brachial plexus, once
considered unresectable is nowadays amenable to advanced techniques of spinal reconstruc‐
tion and should be planned jointly with a spine neurosurgeon. Finally, according to recent
reports [16, 17], the rate of R0 resection could be above 85%, with the use of tri-modality
protocols.
Contraindications for surgery would be due to metastasis, invasion of the brachial plexus
above C7 & invasion of the spinal canal. Resection of the T1nerve root is usually well tolerated,
but removal of the C8 root or lower trunk of the brachial plexus leads to loss of hand and arm
function. N2 disease is a relative contraindication and some groups enrol those patients after
extended hilar radiation. As per JCOG [17]rib involvement occurs in 77.2% of the patients
(usually 3 ribs or more), vertebra involvement in 10.5% of the patients, and major vessels in
5.3%. T1 involvement is the commonest root involved in up to 85% of the cases.
4. Various treatment modalities and tumour down-staging
According to Wright et al [10], marked difference in pathologic response based on the
induction therapy is favouring CT/RT. Surgical resection of Pancoast tumours after neoadju‐
vant high-dose CT/RT was carried out in 40.5% of patients according to Kwong et al [18].
Pathological downstaging although it does not correlate with the radiological appearance [16]
is reported to be impressively above 30% in various series. As per Pourel et al [15], pathological
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complete response was observed in 39.5% of the patients, necrosis of tumoural tissues between
50% and 95% in 22.5% and less than 50% in 38% of the patients. Along the same lines JCOG
reported [17] pathologic downstaging of the tumour in 40% of the patients; No residual viable
tumour cells in the resected specimens, was achieved in 16% of the treated patients. Finally
SWOG [16] summarised that pathologic no residual microscopic tumour was seen in one third
of the resected specimens and minimal microscopic residual (few scattered tumour foci within
a mostly necrotic or fibrotic mass), was observed in one third of the resected specimens.
5. What are the various surgical approaches
The approach of Paulson [19] is completely satisfactory in dealing with posteriorly located
tumours; however, it is not fully adequate in the presence of invasion of anteriorly located
structures (especially subclavian vessels or their branches). Therefore, different anterior
approaches have been developed in the last 25 years, including the cervicosterno-thoracoth‐
omy[20] or the hemi-clamshell incision [21, 22], the transcervical-transthoracic approach with
resection of the clavicle [23, 24], and the trans-manubrial approach [25]. Exact indications for
these different approaches remain controversial, and few data are available about long-term
outcome of patients treated by anterior approaches [22, 24, 26].
Posterior approach (Paulson)/ posterolateral-paravertebral thoracotomy: This is an extension
of the conventional postero-lateral thoracotomy; the incision is extending around the tip of the
scapula, then it continuous upwards and further midway between the posterior edge of the
scapula and the spinous processes, up to the level of C7. By taking the scapula of the chest wall
this incision allows good exposure of the posterior chest wall, including the transverse
processes, the vertebrae and the roots of the thoracic nerves and the plexus [27]. Nevertheless
the exposure of the neuro-vascular structures are limited. This is due to the fact that brachial
plexus and vascular structures often lie above the tumour mass and access to such structures,
is significantly limited using approaches from below.
According to Vanakesa et al [28], Posterior approach, does not provide adequate access to the
many important structures which may be involved by apical chest tumours of bronchogenic
origin. This restricted access may be one of the reasons for the high rate of incomplete resections
[29] and high surgical morbidity and mortality using this approach [10]. The anterior-cervical
entry [24] proved to be the answer to the problem of limited exposure. It appears to be the
optimal approach to anterior lung apex or first rib lesions [30].
We would facilitate a case like the one presented in Figure 1 by using an anterior-manubrial-
sternal approach for access.
Accurate and thorough staging & re-staging (Radiological response is defined according to
the RECIST criteria [31]following neoadjuvant treatment is necessary prior to surgery (see
Figure 2) and typically includes CT-PET and magnetic resonance imaging (Contrast-enhanced
MRI of Chest and Brain). MRA is a noninvasive diagnostic method complementary to MR
imaging for detecting vascular involvement in bronchogenic carcinoma with Pancoast
syndrome [32].
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Figure 1. CXR, CT Chest imaging, MRI and bone scan of a Pancoast tumor of a 47 yrs old female, Ex smoker (25 cigs
per day up to 13 years ago). Six weeks history of shoulder pain radiating to the median aspect of the right arm. CXR
mass at apex of right chest. Percutanteous Biopsy NSCLC. PMH: Hysterectomy for Ca cervix 1996 - no evidence of re‐
currence. Clinical examination fullness in right supra-clavicular fossa.
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Figure 2. Staging algorithm for patients prior to resection of a Pancoast Tumor. MRI of the thoracic inlet may yield
further information's on the status of vertebra involvement.
Figure 3. Root of neck anatomy, depicting carefully the relationship of the most important neurovascular structures to
the scalene musculature and the first rib.
Principles and Practice of Cardiothoracic Surgery114
Root of neck anatomy as in Figure 3 is depicting carefully the relationship of the most important
neuro-vascular structures to the scalene musculature and the first rib. The anterior and middle
scalene muscles are attached to the first rib and can be used as landmarks: in front of the
anterior scalene muscle situated the subclavian and internal jugular veins and the sternoclei‐
domastoid and omo-hyoid muscles.
The subclavian artery, the trunks of the brachial plexus, and the phrenic nerve are emerging
above the lateral part of the1st rib between the anterior and middle scalene muscles. The nerve
roots of the brachial plexus, the stellate ganglion, and the vertebral column are situated behind
the middle scalene muscle.
6. Exposure and surgical steps (Figure 4)
We favour a modified Dartevelle approach [24] an L shaped incision at the anterior edge of
Sterno-cleido-mastoid (a). Division of the upper sternum extended into 2nd intercostal space
(b). This is a modified access something between Grunenwald [25] and Klima et al [33]
approach. Grunenwald has described a trans-manubrial approach, which avoids division of
the clavicle. Klima and colleagues suggested extending the L-shaped section of the manubrium
down to the first intercostal space. We prefer to divide the sternum down to the angle of Luis
and then extend the incision horizontally along the 2nd intercostal space, thus allowing the
surgeon to lift the clavicle, subclavian muscle, and transected part of the manubrium and
superior body of the sternum without dividing the first costal cartilage and ligament. The
internal mammary artery is encountered and divided during the horizontal intercostal
incision.
Mobilisation & excision of the supra-clavicular fat pad (c), allows exposure of the structures
at the thoracic inlet; further division of the subclavious, omohyoid with preservation of the
accessory nerve is carried out.
The distal part of the jugular veins is divided to expose the subclavian and innominate veins.
If the subclavian vein is affected then it is resected. Following this, the scalenus anterior muscle
is divided by taking care to preserve the phrenic nerve (d) & (e). The subclavian artery is
mobilised by, dividing most of its branches. Care is taken to preserve the vertebral artery and
resection of the vessel is done only if it is involved with the tumour and no substantial extra-
cranial occlusive disease can be detected on preoperative Doppler ultrasound.
If the subclavian artery is taken up by tumour, the affected portion is resected and recon‐
structed, usually with a 6-8 mm PTFE vascular graft. Small dose of heparin is usually admin‐
istered during vascular clamping.
Following anterior traction of the subclavian artery, the scalenus medius muscle comes into
good view. The muscle is divided above its insertion on the first rib, giving access to the
branchial plexus. Familiarity with the anatomy of the plexus is important. At this stage, the
anterior surface of the vertebral bodies of C7 and T1 are in view. The sympathetic chain and
stellate ganglion are lying in front of the anterior surface of the vertebral bodies of C7 and T1.
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The C8 and T1 nerve roots are visualised and dissected medially up to the lower trunk of the
brachial plexus. The C8 nerve component of the plexus is preserved if possible, for better
functional outcome of the upper limp.
Care is taken then, to access tumour invasion and plan with the neurosurgeon the “spinal
component” of the operation.
Chest wall resection is carried out by dividing the first 2-3 ribs at the sternal-costo-chondral
junction following by disarticulation of the ribs from the transverse processes at the back. The
Figure 4. Step by step resection of a Pancoast tumor through an Antero-cervical approach. Incision at the anterior edge of
Sterno-cleido-mastoid (a). Division of the upper sternum extended into 2nd intercostal space(b). Mobilisation-Excision of
supraclavicular fat pad (c). Exposure of the structures at the thoracic inlet by dividing the subclavius, omohyoid with preser‐
vation of the accessory nerve. Division of the Scalenus anterior with preservation of the phrenic nerve (d) & (e). Right upper
Lobectomy (f): can be performed through the neck incision or a posterolateral thoracotomy.
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last part of the resection consists of the upper Lobectomy (f). The access to perform a lobectomy
and mediastinal lymph node clearance through the anterior incision is usually limited,
therefore like others [34] we perform a traditional postero-lateral thoracotomy through the
5th inter-costal space. Routine coverage of the bronchial stump with an intercostal or serratus
muscle flap is advocated by some groups [18] to counteract any potential damage on the stump
from the neoadjuvant radiation. Chest wall reconstruction may be necessary in up to 40% of
the cases [34].
For Pancoast carcinomas affecting the spine, a posterior midline approach can be added by a
neurosurgeon, for multilevel unilateral laminectomy[35], nerve root division inside the spinal
canal, and vertebral body division along the midline. The tumour then is removed en bloc with
the lung, ribs, and vessels through the posterior incision. Fixation of the spine is mandatory.
7. Anterior approach: Advantages and dis-advantages
7.1. Advantages
According to Machiarini et al [36] one of the major advances in the treatment of Pancoast
tumours has been the introduction of anterior approaches for resection. These approaches
increase the likelihood of complete resection and permit resection of tumours that were
previously considered technically unresectable [37].
Furthermore anterior approach facilitates: 1) Direct visualisation of major structures (eg.
Subclavian artery, superior vena cava) thus allowing control and elective sacrifice of the artery
if necessary and reconstruct directly to a safe outcome. 2) Excellent exposure of the brachial
plexus, sympathetic chain, and stellate ganglion. 3) Carry out hemi-vertebrectomy if the
anterior body of the vertebra are involved. 4) Resection of the lower parts of the Brachial plexus,
especially of the C8, T1 roots; however T1 root resection results in diffuse weakness of the
intrinsic muscles of the hand, whereas resection of the C8 nerve root of the lower trunk of the
brachial plexus results in permanent paralysis of the hand muscles. 5) Optimal access, for
resection of the chest wall. 6) Oncological clearance of the structures of the Thoracic inlet,
because the tumour is the last to be encountered. 7) Lower morbidity than the posterior
approach.
Moreover as per Vanakesa et al [28]the cervical-trans-sternal approach has several advantages,
chiefly that of avoiding disfigurement and loss of function of the pectoral girdle, whilst
providing excellent exposure of the brachial plexus, sympathetic chain, and stellate ganglion.
Such an approach results in a short postoperative stay (3–6 days), and yet allows extension as
per Grunenwald [25], or by a high, anterior thoracotomy if necessary.
7.2. Disadvantages
Removal of transverse processes and the head of the ribs in order to disarticulate them, could
be difficult with the anterior access; furthermore more posterior seated tumours with vertebra
involvement may require a complimentary posterior incision.
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There are concerns about functional and aesthetic results with the trans-clavicular approach,
which includes removal of the medial half of the clavicle.
8. Results from literature review
Unfavourable outcome is due to incomplete resection and life-threatening complications
Current reports are quoting peri-operative mortality not higher than for any other lung
resection [16, 17].
The prognosis of this tumour remained poor until 1961 when Shaw et al [38] reported their
satisfactory experience with a bi-modality treatment based on preoperative radiotherapy
followed by surgery through a posterior thoracotomy approach. Several other reports [2, 10,
19, 29, 38-41] confirmed that 5-year survivals of approximately 10 to 35% could be achieved
with this combined approach, which became the standard treatment. Although radiotherapy
was performed prior to surgery in most series, in the experience of others [24, 26]it was often
carried out postoperatively.
Adverse prognostic factors are including the presence of mediastinal nodal metastases (N2
disease), spine or subclavian-vessel involvement (T4 disease), and limited resection (R1 or R2)
[42-44]. Along the same lines Ginsberg et al [2] found Horner’s syndrome, N2/N3 disease, T4
disease and incomplete resection, in general, to be adverse prognostic factors. Okubo and
associates [29][16] found that incomplete resection particularly tumour invasion to the brachial
plexus, influenced the prognosis.
9. Recurrence & survival
With bi-modality regimes the local recurrence rates were reported to be above 70% [10, 13].
Despite the advent in treatment regimes, local recurrence still occurs in about 40% of the
patients [43]; it is expected that local recurrence rate is higher in patients with T4 disease
because complete resection can be achieved in less than half of the patients with c-T4 disease
[17]. More specifically [44] complete resection rate was achieved in only 64% of tumour stage
T3 and nodal stage N 0 and 39% of T4N0 tumours. It is apparent however, that loco-regional
relapse is predominant in R1-2 resections, whereas distant recurrence is frequent in R0
resections.
One would expect that a shift in the trend of clinical recurrences towards distant metastasis is
to be currently expected because of the fact that tri-modality treatment facilitates better R0
resection. As per Pourel et al [15] the most frequent site of relapse was distant metastasis in
66% of the patients, (mainly brain) with the loco-regional recurrence rate of 18%. Likewise
Kwong et al [18] reported brain metastasis in 25% and local recurrence rate in 19% of the cases.
A small series that had bi-modality treatment however had an incidence of loco-regional
recurrence of 17.2% [14].
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Survival has been extensively reviewed by Attar et al [45]. Overall survival at 5 years after
surgery was 46% for T3N0, 13% for T4N0, and 0% for lesions with N2 disease [44]. Particularly
noteworthy [17]was the reproducibility of the favourable survival data, with a 5-year overall
survival rate of 44% in the United States trial (SWOG) and 56% in JCOG trial, which were
clearly superior to the historical value of 30%.
There is wide variability in overall 5-year survival rates reported in larger series,[19, 24, 26, 39,
41, 44, 46] with figures ranging 10 to 35% probably because of the heterogeneity in studied
populations, operative techniques, and preoperative and postoperative treatments. Such
heterogeneity is probably responsible for the difference in the percentage of T3 and T4 tumours
as well as in the rates of complete resection. Comparison of long-term results of different
studies is difficult also for the frequent lack of information about survival according to the
pathologic stage.
10. Future thoughts
In the future new neoadjuvant regimes including aggressive protocols of accelerated radio‐
therapy would potentially increase the pool of surgical candidates from patients diagnosed
with a Pancoast tumour (currently 23% of the patients as per Kappers et al [13]. However,
several questions still remain unresolved:
1) The role of PET-CT in re-staging tumours (eg. The role of “late wash out” images in
differentiating between inflammation and residual tumour) following neo-adjuvant treat‐
ment; Schmuecking et al [47] have shown that metabolic response after induction CT/RT
evaluated within 1 week following its completion, is highly predictive of pathological
response. 2) What is the significance and implications of ipsilateral supra-clavicular lymph
node disease: The argument being that these nodes are in close vicinity of the tumour and
therefore could have the characteristics of the biological behaviour of “N1 disease”. 3)
Recruiting patients with N2 disease: The argument being that inclusion of the hilar and
mediastinal nodes in the irradiation field promotes downstaging. Kwong et al [18] did not
exclude patients with positive mediastinal nodes from tri-modality treatment and found no
difference in survival. In most papers, however, results of patients with persistent N2 disease
turned out to be clearly inferior to those of patients with N0/1 only. On the other hand, no
clinical trial has yet compared various tri-modality treatment regimes for patients with N2
disease. 4) The role of prophylactic cranial irradiation: Due to good loco-regional control with
tri-modality treatment, distant metastases now represent the most common site of failure.
Furthermore, the incidence of brain metastasis as a first site of recurrence in Pancoast tumour
is between 15-30% [34, 48]. The negative impact of brain metastasis on survival has to be
weighted against the risks benefits ration of the impact of prophylaxis with radiation to the
brain. 5) The role of high dose of RT (up to 60Gy): Are there specific subgroups (eg. for patients
with clinical T4 disease complete resection is feasible in less than 50% of the cases) that they
would benefit. 6) The role of Adjuvant postoperative chemotherapy: distant metastases now
represent the most common site of failure following treatment for Pancoast tumours therefore
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preventing distant metastasis has now become the challenge in the treatment of these patients.
Large randomised trials concluded a 5—15% survival benefit at 5 years of adjuvant chemo‐
therapy in patients with radically resected stages I—IIIA NSCLC [49, 50]. However, many
patients with Pancoast tumours may not tolerate more extensive treatment. Moreover
Martinod et al [26] reported that preoperative radiotherapy significantly improved the 5-year
survival for stage IIB—IIIA, while postoperative radiotherapy and chemotherapy did not
significantly alter survival. 7) Is the Survival with the use of anterior approach better versus
posterior approach for the same stage of Pancoast tumours?
11. Conclusion
Pancoast tumours represent a small percentage of Lung cancer population (1-5%). Due to poor
performance status and/or advanced tumour stages, only 30-40 % [10, 13] of those patients are
eligible to be enrolled in multi-modality protocols of treatment.
Careful patient selection and adherence to protocols enables Clinical groups to get an impres‐
sion of the efficacy of an intervention and to compare results between studies.
Superior sulcus tumours remain an extremely severe condition, but cure may be achieved in
a large percentage of cases. The surgical approach should be adapted to the different clinical
and radiologic presentations in order to achieve a complete surgical resection, which repre‐
sents the most important positive prognostic factor. Surgery carries a high operative risk,
especially if a combined approach is needed, so every effort should be made to identify patients
expected to derive a benefit that outweighs risks.
No single surgical approach however, provides the best access to all of the heterogeneous
tumours of the thoracic inlet. The thoracic surgeon must be familiar with the potential
advantages that the anterior approach offers under given circumstances. This knowledge
enables the thoracic surgeon to explore new avenues and exciting challenges. Dartevilles
approach and the various modifications are technically demanding, however once the
anatomy has been appreciated, direct visualisation of the major structures of the Thoracic inlet
aids to facilitate complete oncological clearance. Whether the anterior approach results in less
loco-regional recurrences and possibly better 5 year survival, remains to be seen.
12. Summary
12.1. Introduction
Pancoast syndrome is due to lesions extending to the superior thoracic inlet. Pancoast tumour
is a tumour of the apex of the lung with no intervening lung tissue between tumour and chest
wall. The tumour rapidly involves the structures of the thoracic inlet & the root of neck.
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Pain at the ulnar aspect of the forearm and hand is consistent with T1 involvement; furthermore
symptomatology along the intrinsic hand muscles suggests the C8 root or lower trunk tumor
deposits.
An understanding of the posterior location of neural structures and somewhat anterior
location of vascular structures is important for adequate operative planning.
Pancoast tumours were thought to be located posteriorly and early attempts to resect those
tumors were approached solely from the back. A percentage of these lesions might also be
located at the front, with vascular rather than neuro- vertebral involvement. Therefore
surgeons treating these cancers should be able to be familiar and adapt with the various
approaches.
12.2. Surgical Approaches
1. Posterior approach (Paulson)/ posterolateral-paravertebral thoracotomy: This is an
extension of the conventional postero-lateral thoracotomy; the incision is extending
around the tip of the scapula, then it continuous upwards and further midway between
the posterior edge of the scapula and the spinous processes, up to the level of C7. By taking
the scapula of the chest wall this incision allows good exposure of the posterior chest wall,
including the transverse processes, the vertebrae and the roots of the thoracic nerves and
the plexus. Never the less the exposure of the neurovascular structures are limited.
2. The anterior-cervical approach proved to be the answer to the problem of limited
exposure. It appears to be the optimal approach to anterior lung apex and first rib lesions.
We favour a modified Dartevelle approach We prefer to divide the sternum down to the angle
of Luis and then extend the incision horizontally along the 2nd intercostal space, thus allowing
the surgeon to lift the clavicle, subclavian muscle, and transected part of the manubrium and
superior boby of the sternum without dividing the first costal cartilage and ligament.
Mobilisation & excision of the supraclavicular fat pad, allows exposure of the structures at the
thoracic inlet; further division of the subclavius, omohyoid with preservation of the accessory
nerve is carried out.
The distal part of the jugular veins is divided to expose the subclavian and innominate veins.
If the subclavian vein is affected then it is resected. Following this, the scalenus anterior muscle
is divided by taking care to preserve the phrenic nerve.
The subclavian artery is mobilized by, dividing most of its branches. Care is taken to preserve
the vertebral artery and resection of the vessel is done only if it is involved with the tumor and
no substantial extracranial occlusive disease can be detected on preoperative Doppler ultra‐
sound.
12.3. The advantages of the anterior- cervical approach
1. Direct visualization of major structures (eg. Subclavian artery), allowing control and
elective sacrifice if necessary the artery and reconstruct directly to a safe outcome.
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2. Carry out hemi-vertebrectomy if the anterior body of the vertebra are involved.
3. Provide complete oncological clearance of the structures of the Thoracic inlet. The
structures which may be sacrificed if involved are the Subclavian artery, the Brachial
plexus the T1 nerve root and Vertebral body
12.4. Down-staging
Pathological down-staging although it does not correlate with the radiological appearance is
reported to be impressively above 30% in various series.
JCOG reported pathologic down-staging of the tumour in 40% of the patients; No residual
viable tumour cells in the resected specimens, was achieved in 16% of the treated patients. Also
SWOG summarised that pathologic no residual microscopic tumour was seen in one third of
the resected specimens and minimal microscopic residual (few scattered tumour foci within a
mostly necrotic or fibrotic mass), was observed in one third of the resected specimens.
12.5. Results
Unfavorable outcome is due to incomplete resection and life-threatening complications.
Current reports are quoting perioperative mortality not higher than for any other lung
resection.
Adverse prognostic factors are including the presence of mediastinal nodal metastases (N2
disease), spine or subclavian-vessel involvement (T4 disease), and limited resection (R1 or R2.
Author (year) No. of Cases 5 year survival (%) Mortality (%)
Paulson DL (1985) 79 35 3
Maggi et al (1994) 60 17.4 5
Ginberg et al (1994) 100 26 4
Okubo et al (1995) 18 38.5 5.6
Hagan et al (1999) 34 33 0
Dartevelle P (1999) 70 34 0
Table 1. Survival with the use of the anterior versus posterior approach
12.6. Recurrence
With bimodality regimes the local recurrence rates were reported to be above 70%. Despite the
advent in treatment regimes, local recurrence still occurs in about 40% of the patients; it is
expected that local recurrence rate is higher in patients with T4 disease because complete
resection can be achieved in less than half of the patients with c-T4 disease.
More specifically complete resection rate was achieved in only 64% of tumour stage T3 and
nodal stage N 0 and 39% of T4N0 tumours.
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It is apparent however, that locoregional relapse is predominant in R1-2 resections, whereas
distant recurrence is frequent in R0 resections.
In the future new neoadjuvant regimes including aggressive protocols of accelerated radio‐
therapy would potentially increase the pool of surgical candidates from patients diagnosed
with a Pancoast tumor (currently 23% of the patients as per Kappers et al). However, several
questions still remain unresolved such as the role of PET, nodal involvement especially
recruiting patients with N2 disease. Lastly the role of trimodality treatment and prophylactic
cranial irradiation
12.7. Conclusion
Pancoast tumors represent a small percentage of Lung cancer population (1-5%). Due to poor
performance status and/or advanced tumor stages, only 30-40 % of those patients are eligible
to be enrolled in multimodality protocols of treatment.
No single surgical approach however, provides the best access to all heterogeneous tumors of
the thoracic inlet. What probably provides the most favorable outcome would be a team
approach, where the thoracic surgeon coordinates with an experience neuro-spinal surgeon,
in a background of limited disease that is responding well to neoadjuvant chemoradiotherapy.
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